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ABSTRACT 
Ornithine decarboxylase (ODC) is the first and rate-limiting 
enzyme in the synthesis of polyamines, which play a regulatory role 
in nucleic acid and protein synthesis. The enzyme may be involved in 
normal and abnormal growth of the myocardium, in the relationship 
between mechanical stress and protein synthesis, and in the 
development of left ventricular hypertrophy (LVH). Results from this 
and other laboratories suggest that experimental diabetes has a more 
profound effect on mechanical function and cellular growth of 
hypertrophic heart muscle than it does on nonhypertrophic tissue. 
Diabetes is associated with reduced serum levels of both insulin and 
thyroid hormone. Both of these hormones are demonstrated regulators 
of ODC activity. Despite this, relatively little is known about the 
effects of diabetes on cardiac ODC activity and polyamine synthesis 
in the presence or absence of LVH. Therefore, we have hypothesized 
that: 1) ODC activity of hypertrophic left ventricle in spontaneously 
hypertensive rat (SHR) is higher than that of nonhypertrophic left 
ventricle in the normotensive rat strains, Wistar Kyoto (WKY) and 
Sprague Dawley (SD); 2) Untreated diabetes will reduce left 
ventricular ODC activity of SHR and of nonhypertensive rats, but its 
effects on the former will be greater in magnitude; 3) The effects of 
diabetes on left ventricular ODC activity, of either SHR or 
normotensive rats, will be preventable with insulin treatment, and at 
least partially preventable by thyroid hormone treatment, in vivo. 
Diabetes was induced in SHR and WKY by Streptozotocin (STZ) at 15 
weeks of age. Subgroups were treated with insulin or 
ii 
triiodothyronine (T3). After 8 weeks of treatment, left and right 
ventricles were assayed for ODC activity, by measuring the rate of 
evolution of 14co2 from (1-
14c) L-ornithine. The results show that 
left ventricular ODC activity of nondiabetic SHR was not 
significantly different from that of either the WKY or SD 
normotensive rats. Streptozotocin-induced diabetes reduced left 
ventricular ODC activity to about the same extent in the hypertrophic 
SHR and in the nonhypertrophic WKY, depressing V without affecting 
max 
the apparent K of the enzyme in both strains. However, experimental 
m 
diabetes had no effect on right ventricular ODC activity in either 
the SHR or WKY strains. Both insulin and T3 treatment were partially 
effective in preventing the reductions in ODC activity caused by 
diabetes. The results show that the depression in ODC activity 
caused by untreated diabetes 1) Is selective for the left 
ventricle perhaps because of its relatively greater workload; 2) Is 
not selective for the hypertrophic ventricle in the SHR strain; and 
3) May be related, in part, to the effects of the hypothyroidism 
which attends diabetes. These results do not support a causal 
relationship between left ventricular ODC activity and the 
maintenance of hypertrophy, nor do they support a predisposition of 
left ventricular hypertrophy to influences of diabetes on ODC 
activity (Hypotheses 1 and 2). The results do support a 
participation of attendant hypothyroidism in the effects of diabetes 
on left ventricular ODC activity (Hypothesis 3). 
iii 
ACKNOWLEDGEMENT 
The author would like to thank Dr. Robert Rodgers for his utmost 
patience, moral support, and guidance throughout the course of this 
study. 
I would like to dedicate this thesis to my wife, Barbara. 
Without her love, support, and understanding, this work could not 
have been completed. Finally, I would like to thank special friends 
Amy Davidoff, Mark Mariani, and Francine Pinault for all of their 
help. 
iv 
PREFACE 
This thesis was prepared according to the manuscript format and 
is being submitted to the American Journal of Physiology. 
v 
TABLE OF CONTENTS 
PAGE 
ABSTRACT. • • • • • • • • . • . • • • • • . • • • • • • . • • • • • • • • • . . • • • . • • • • • . ii 
ACKNOWLEDGEMENTS • • • • • • • • • • • • • • • . • • • • • • • • • • • • . • • • • • • • • • iv 
PREFACE •••••••••••••.•••••••••.••••••.•••••••••.••.••• v 
TABLE OF CONTENTS •••••••••••••••.••••.••••••.•••••.••• vi 
LIST OF TABLES •••••••••••••••.•••••••••.••..••••••.••• vii 
LIST OF FIGURES ••••••.•••••••••••••••••••••••••••••••• viii 
ABSTRACT •••.•••••••••••••••••••••••••••••••••••••.•••• 2 
INTRODUCTION. • • • • • • • • • • • . • • . • • • • • • • • • • • • • • • • • • . • • • • • • . 4 
MATERIALS AND METHODS ••••••••.••.••••••••••••.••.••.•• 8 
RESULTS •••••••••••••••••••••••••••••••••.•••••••.••••• 13 
DISCUSSION. • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • . • • • . • . • • 23 
REFERENCES. • • • • • • • • • • • • • • • . • • • • • • • • • . • • • • • • . • • • • • • . • • . 34 
APPENDIX-RESULTS ANCILLARY TO MANUSCRIPT ••••••••••••.• 41 
BIBLIOGRAPHY. • • • • . • • • • • • • • • • • • • • • • • . • • • • • • • • • . • • • . . • • . 54 
vi 
LIST OF TABLES 
PAGE 
MANUSCRIPT 
TABLE 1: Serum glucose, insulin, T3 and T4 ........•..•. 16 
TABLE 2: Systolic arterial pressure and heart rates ..... 17 
TABLE 3: Body and heart weight ratios •.................. 18 
TABLE 4: Left ventricular ODC activities ................ 19 
TABLE 5: ODC kinetics ................................... 22 
APPENDIX 
TABLE 6: ODC activity at saturating ornithine 
concentration .................................. 50 
TABLE 7: Right ventricular ODC activities ............... 51 
TABLE 8: Subcellular localization of ODC ................ 52 
TABLE 9: Myocardial arginase activity ..................• 53 
vii 
LIST OF FIGURES 
PAGE 
MANUSCRIPT 
FIGURE 1: Ventricular ODC kinetics .................... 21 
APPENDIX 
FIGURE 2: Characterization of ODC ..................... 43 
FIGURE 3: Effect of increasing concentrations of 
enzyme supernatant on ODC activity .......... 45 
FIGURE 4: Verification of linearity of enzyme assay 
with time .............•.•.........•......... 47 
FIGURE 5: Verification of 14co2 recovery by base-
trap technique. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 
viii 
MYOCARDIAL ORNITHINE DECARBOXYLASE OF HYPERTENSIVE 
AND DIABETIC RATS: EFFECTS OF INSULIN AND 
TRIIODOTHYRONINE TREATMENT 
ABSTRACT 
Ornithine decarboxylase (ODC) is the first and rate-limiting 
enzyme in the synthesis of polyamines, which play a regulatory role 
in nucleic acid and protein synthesis. The enzyme may be involved in 
normal and abnormal growth of the myocardium, in the relationship 
between mechanical stress and protein synthesis, and in the 
development of left ventricular hypertrophy (LVH). Results from this 
and other laboratories suggest that experimental diabetes has a more 
profound effect on mechanical function and cellular growth of 
hypertrophic heart muscle than it does on nonhypertrophic tissue. 
Diabetes is associated with reduced serum levels of both insulin and 
thyroid hormone. Both of these hormones are demonstrated regulators 
of ODC activity. Despite this, relatively little is known about the 
effects of diabetes on cardiac ODC activity and polyamine synthesis 
in the presence or absence of LVH. Therefore, we have investigated 
the possible role of ODC in LVH in the spontaneously hypertensive rat 
(SHR) and in the non-hypertensive Wistar Kyoto (WKY) and Sprague 
Dawley (SD) strains. We also examined the effects of diabetes on 
cardiac ODC activity in the presence and absence of LVH. The results 
show that left ventricular ODC activity of nondiabetic SHR was not 
significantly different from that of either the WKY or SD 
normotensive rats. Streptozotocin-induced diabetes reduced left 
ventricular ODC activity to about the same extent in the hypertrophic 
SHR and in the nonhypertrophic WKY, depressing V without affecting 
max 
the apparent K of the enzyme in both strains. However, experimental 
m 
diabetes had no effect on right ventricular ODC activity in either 
2 
the SHR or WK.Y strains. Both insulin and triiodothyronine (T3 ) 
treatment were partially effective in preventing the reductions in 
ODC activity caused by diabetes. The results show that the 
depression in ODC activity caused by untreated diabetes 1) Is 
selective for the left ventricle perhaps because of its relatively 
greater workload; 2) Is not selective for the hypertrophic ventricle 
in the SHR strain; and 3) May be related, in part, to the effects of 
the hypothyroidism which attends diabetes. 
3 
INTRODUCTION 
The polyamines - putrescine, spermidine, and spermine - play an 
important regulatory role in nucleic acid and protein synthesis and 
cellular growth (23, 47, 72, 73). The initial step in their 
formation is catalyzed by ornithine decarboxylase (ODC, EC 4.1.1.17), 
which converts ornithine to putrescine, and appears to be the 
rate-limiting enzyme for polyamine synthesis (44, 61). one is 
unique in that its half-life is approximately 10-20 minutes, the 
shortest of any known mammalian enzyme (40, 64). The activities of 
one and putrescine fluctuate rapidly and specifically in response to 
a variety of hormonal and metabolic factors that alter cell growth 
(73). Thus one is markedly increased in tissues in which growth is 
accelerated, and its activity is usually low when the rate of growth 
is slow (11). 
Cardiac hypertrophy is an early adaptive response to increased 
functional demand on the heart, such as pressure or volume overload 
(52, 80). The message by which increased mechanical stress is 
translated into increased protein synthesis and hypertrophy is not 
clear (60, 84). As a growth-regulating enzyme, ODC is a plausible 
point of control in the hypertrophy process. However, the extent to 
which ODC may contribute to the development and maintenance of 
myocardial hypertrophy is not well defined. The activity of ODC is 
normally higher in the left ventricle than in the right, which seems 
to be a reflection of the relatively greater work required of this 
chamber (6). A rise in ODC activity is a well documented biochemical 
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event in the development of hypertrophy in a variety of tissues (3, 
21). Previous studies have shown an increase in polyamine 
concentration and cardiac one activity in the hypertrophic response 
to aortic constriction (17, 40), catecholamines (3, 4, 9, 22, 30), 
thyroid hormone (12, 13, 45, 46, 54) and hypoxia (32, 55). The fact 
that stimulation of myocardial one activity precedes the development 
of hypertrophy suggests that increased polyamine synthesis may be an 
important regulatory component of cardiac hypertrophy (39, 40, 60, 
62). In fact, a temporal relationship has been described by 
Calderera et al. (10) between an increase in polyamine concentration 
which precedes an increase in RNA synthesis during the early stages 
of exercise-induced cardiac hypertrophy. In addition to these acute 
studies, the results of Ruskoaho et al. (60) show that the onset of 
left ventricular hypertrophy over time in the spontaneously 
hypertensive rat (SHR) model of hypertension is associated with 
elevated left ventricular ODe activity. Boucek et al. (7) have shown 
that changes in tension development alone in isolated rabbit 
papillary muscles can stimulate one activity. 
It is well known that diabetes diminishes protein and RNA 
synthesis (16, 43) and accelerates protein degradation (81) in a 
variety of tissues, including cardiac muscle. Previous studies in 
this and other laboratories have also shown that diabetes reduces 
heart size, and in the SHR model of hypertension may also reverse 
left ventricular hypertrophy (15, 58, 70). Despite this, relatively 
little is known about the effects of diabetes on cardiac ODC activity 
and polyamine synthesis in the presence or absence of hypertension. 
Indeed, the influence of diabetes on one activity in any tissue is 
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not well characterized. Levine et al. (36) and Brosnan et al. (8) and 
others (25, 59) have reported an increase in ODC activity in liver 
and kidney of diabetic normotensive rats. However, Sochor et al. 
(69) and Conover et al. (14) both reported profound decreases in ODC 
activity in liver and heart of diabetic rats which could be prevented 
with insulin treatment. The effect of diabetes on myocardial ODC 
activity has not been investigated in any model of cardiac 
hypertrophy. 
An attendant hypothyroidism, or "low thyroid state" (53), is 
often associated with human and experimental diabetes. 
Hypothyroidism alone decreases myocardial ODC activity (13), and 
thyroid hormone is an established regulator of myocardial ODC 
activity (12, 13, 54). Thus, studies of the effects of experimental 
diabetes on ODC activity should be designed to take into account the 
possible influence of attendant hypothyroidism. 
The central hypotheses of the proposed study can be stated as 
follows: 1) ODC activity of hypertrophic left ventricle in SHR, at a 
given age, is higher than that of nonhypertrophic left ventricle in 
normotensive rat strains; 2) Untreated diabetes of moderate severity 
and eight weeks duration will reduce left ventricular ODC activity of 
SHR and of nonhypertensive rats, but its effect on the former will be 
greater in magnitude; 3) Effects of diabetes on left ventricular ODC 
activity, of either SHR or normotensive rats, will be preventable 
with insulin therapy, and at least partially preventable by thyroid 
hormone treatment, in vivo. Secondary aims of the study include 
comparisons of left and right ventricular ODC activities of 
6 
nondiabetic SHR and normotensive rats, and analysis of the kinetics 
of ODC obtained from nondiabetic and diabetic rat left ventricle. 
7 
MATERIALS AND METHODS 
Experimental Groups and Treatments. Male Spontaneously Hypertensive 
rats (SHR) and age-matched normotensive control Wistar Kyoto (WKY) 
and Sprague Dawley (SD) rats were obtained from Charles River 
Breeding Laboratories (Wilmington, MA.). The animals were housed in 
temperature-controlled animal rooms (22°C) with a 12-hr light-dark 
cycle (8:00 a.m. to 8:00 p.m.). They were kept in group cages by 
strain and maintained on standard rat chow (Agway Inc., Syracuse, 
N.Y.) and tap water ad libitum. At 15 weeks of age, animals were 
matched according to body weight (BW) and blood pressure (SAP) within · 
strains and divided into either diabetic or nondiabetic groups. 
Diabetes was induced in the SHR and WKY rat strains via a single tail 
vein injection, under light ether anesthesia, of Streptozotocin (STZ, 
Sigma Chemical Co., St. Louis, MO.). The dose of STZ for each strain 
was adjusted in order to induce similar degrees of diabetes as 
assessed by serum glucose concentrations. Based on preliminary 
results, the doses used in this study for SHR and WKY strains were 45 
mg STZ/kg BW and 50 mg STZ/kg BW respectively. The ·sTZ was dissolved 
in citrate buffer (0.1 Mat pH 4.5) just prior to use. The 
nondiabetic animals were also anesthetized and were injected with a 
similar volume of citrate buffer. The duration of either untreated 
or treated diabetes was eight weeks and the extent of diabetes was 
monitored weekly by urinary glucose measurements (Diastix (R)) and 
verified by serum glucose and insulin levels at time of sacrifice. 
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A series of three studies, consisting of separate treatment 
groups, were carried out as follows (see Table 4): 1) A preliminary 
study of the effects of diabetes on left ventricular ODC activities 
in the SHR and WKY rats; 2) The effects of insulin and 
triiodothyronine (T3) treatment of diabetic SHR; 3) The effects of 
insulin and T3 treatment of diabetic WKY. In addition, kinetic 
analyses were performed in Study 3 as described below. The animals 
were divided into experimental and control groups as follows. The 
nondiabetic animals from both SHR and WKY consisted of untreated 
controls and those treated with daily administration of 3,5,3'-
triiodothyronine sodium (T3). Those animals treated with STZ were 
subdivided into diabetic and insulin- and T3-subgroups. Daily 
injections of T3 (lOug/kg BW, Sigma Chemical Co., St. Louis, MO.) 
(74) and Protamine Zinc Insulin (I; 10 U/kg BW, Eli Lilly, 
Indianapolis, IN.) (75) were administered subcutaneously. This dose 
of T3 was selected in previous studies in this laboratory according 
to its ability to prevent diabetes- induced bradycardia and to 
restore low serum thyroid hormone levels of diabetic rats to normal 
(15). 
In vivo measurements. Systolic arterial pressure (SAP), heart rate 
(HR) and body weight (BW) were taken just prior to tail vein 
injections, and then four and eight weeks after STZ injection. A 
standard tail-cuff sphygmomanometer within a temperature controlled 
chamber (34°C) was used to measure SAP and HR, after the animals were 
prewarmed for 20 minutes (51). The SAP reported for each rat is the 
mean of at least six consecutive measurements. All measurements were 
recorded prior to the daily injections of T3 or insulin. 
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Serum assays. After eight weeks of diabetes (at approximately 23 
weeks of age), the animals were sacrificed by decapitation and their 
serum collected and stored at -20°C. Treated animals were always 
sacrificed 15-20 hours after their last daily injection. Serum 
titers of glucose were determined by the glucose oxidase assay 
(Sigma) and used to evaluate the degree of diabetes. Animals were 
classified retrospectively as diabetic if serum glucose values 
exceeded 300 mg/dL. Radioimmunoassays were used to determine serum 
insulin (Micromedic Systems Inc., Horsham, PA.) and total T3 and 
total thyroxine (T4 ) concentrations (Cambridge Medical Diagnostics, 
Billerica, MA.). Rat insulin was generously supplied by Dr . R. 
Chance (Eli Lilly) and was used as the standard for the insulin 
assays. 
Enzyme assays. The heart was quickly excised, rinsed in ice cold 25 
mM HEPES buffer, pH 7.2 
(N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid, Research 
Organics, Cleveland, OH.), and blotted dry. The left ventricle with 
septum was carefully isolated from the right ventricle and each 
weighed separately. The left ventricle was diced and a 5% homogenate 
prepared in hypotonic 25mM HEPES at pH 7.2, using a Bio-Homogenizer 
(Biospec Products, Bartlesville, OK.) and centrifuged at 36,000g for 
20 minutes. Triplicate aliquots of the supernatant fluid were used 
as the source of the enzyme. Right ventricles were quickly frozen in 
0 liquid nitrogen, stored at -80 C and assayed later. 
The activity of ODC was determined by a modification of the 
procedure of Russell and Synder (61). The assay is based on the rate 
of evolution of 14co2 from (1-
14c) L-ornithine (Amersham Corp., 
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Arlington Heights, IL.). The supernatant fluid was added to the 
reaction mixture in a 7 mL glass vial sealed with a rubber stopper 
through which was suspended a plastic center well (Kontes Glassware, 
Vineland, NJ.) containing 0.35 mL of lM KOH and a small piece of 
filter paper. The assay mixture contained the following at the 
designated reaction concentrations in a final volume of 0.5 mL (all 
reagents from Sigma): dithiothreitol, 0.5 mM; pyridoxal phosphate, 
0.05 mM; sodium bicarbonate, 3.0 mM; (1- 14c) L-ornithine, 25 uM,200 
uM, or 400 uM (0.1 uCi; approximately 16,000, 2000, or 1000 
cpm/nmol); and enzyme preparation, 0.3 mL, equally approximately one 
mg of protein. (Values for left ventricular ODC activity at 200 µM 
and 400 uM substrate concentration are in Appendix). In the kinetic 
studies (1- 14c) L-ornithine was isotopically diluted with unlabelled 
L-ornithine to achieve the desired concentrations (6.25 to 300 uM; 
approximately 64,000 to 1,350 cpm/nmol). After diluting the (1- 14c) 
L- ornithine, the open vial was gently stirred at room temperature in 
a fume hood for one to two hours in order to release free 14co2 and 
minimize background (78). Assay blanks contained 0.3 mL of 25 mM 
HEPES in place of cardiac enzyme supernatant and normally averaged SO 
cpm/tube/hr. The lowest signal-to-noise ratio was usually in the 
range of 300 to 500 cpm above background for 25 uM ornithine and 150 
to 200 cpm for 200 uM ornithine. 
The reaction was allowed to proceed for one hour at 37°C and was 
terminated by the injection of 0.3 mL of 3.0 M citric acid through 
the rubber stopper. The 14co2 generated from the decarboxylation of 
(1- 14c) L-ornithine was distilled into the center well during a 
second incubation of one hour. Approximately 96% of the generated 
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14co2 was recovered in one hour (see Appendix). The center wells 
were transferred to scintillation vials for quantification of 
radioactivity (counting efficiency - 85%). Preliminary experiments 
verified that the rate of 14co generation was linear with time and 2 
enzyme concentration (see Appendix). Activity of ODC is expressed as 
pmol of 14co2 generated/hr/mg protein in the cell-free supernatant 
fluid after determination of protein content by the Lowry method 
(37). 
Statistical analysis. The effects of diabetes and the hormone 
treatments were evaluated by one- or two-factor analysis of variance 
(ANOVA) with repeated measures when appropriate, and the Student 
Newman-Keuls test (Statistical Analysis Systems, Cary, NC.) for 
multiple comparisons. Straight lines for kinetic analysis were 
determined by linear regression. A level of significance of p < 0.05 
was considered sufficient. Lower probabilities were not reported. 
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RESULTS 
Serum assays. The effects of STZ-induced diabetes of 8 weeks 
duration on measurements of serum glucose, insulin, T3 and T4 of SHR 
and WKY rats are swmnarized in Table 1. Injection of STZ increased 
serum glucose, and reduced serum insulin of SHR and WKY rats to the 
same extent. By these criteria, the degree of diabetes was 
equivalent in both strains. The diabetic animals of both strains 
were also characterized by depressed serum T3 and T4 levels. The 
magnitude of attendant hypothyroidism was about the same in the two 
diabetic groups, but the T3 levels of nondiabetic SHR were 
significantly higher than those of the nondiabetic WKY. 
Treatment with T3 had no effect on serum glucose or insulin 
levels of any of the experimental groups (Table 1). Treatment of 
diabetic SHR with T3 restored the depressed serum T3 levels to 
normal, and also aggravated the decline in serum T4 , probably by 
inhibiting TSH production by the pituitary and T4 secretion from the 
thyroid gland. T3 treatment of nondiabetic SHR had the same 
depressing effect on T4 levels, but had no effect on the other serum 
measurements. However, the same dose of T3 , when administered to 
either nondiabetic or diabetic WKY, significantly increased serum T3 
levels as well as exacerbating the decline in serum T4 levels. 
Insulin treatment of diabetic SHR did not correct the 
hyperglycemia although it caused a pronounced increase in serum 
immunoreactive insulin activity (Table 1). Insulin treatment did not 
restore serum T3 and T4 levels to normal. In contrast, treatment of 
13 
diabetic WKY with the same dose of insulin effectively reversed the 
hyperglycemia and depressed serum insulin levels, and corrected the 
reductions in serum T3 and T4 levels. 
Arterial Pressure and Heart Rate In Vivo. Nondiabetic SHR were 
hyper-tensive and tachycardic compared to nondiabetic WKY and SD rats 
at both Week 0 and Week 8 (Table 2). Diabetic SHR were characterized 
by depressed SAP and HR after 8 weeks, confirming previous results 
(58). Diabetes had no significant effect on either SAP or HR in the 
WKY strain. Treatment of diabetic SHR with either insulin or T3 was 
sufficient to prevent the decrease in both SAP and HR. Treatment of 
nondiabetic SHR with T3 had no effect on either SAP or HR, but 
administration of the same dose of T3 to diabetic and nondiabetic WKY 
rats did cause significant elevations in both SAP and HR. 
Body and Heart Weights. Left ventricles of SHR were hypertrophic, 
both relatively (LVW/BW) and absolutely (LVW/RVW) compared to left 
ventricles of the nonhypertensive WKY and SD rats (Table 3). 
Diabetes reduced BW, left ventricular weight (LVW), and right 
ventricular weight (RVW) of SHR, but did not have a significant 
effect on indices of left ventricular hypertrophy . Diabetes reduced 
BW in WKY rats but had no effect on left or right ventricular 
weights. The effects of diabetes on heart weights (LV and RV) were 
more pronounced in the SHR than they were in the WKY strain. 
Insulin treatment of diabetic SHR either partially or fully 
restored BW, LVW, and RVW, but had no effect on LVW/BW or LVW/RVW 
(Table 3). Insulin treatment effectively restored BW of diabetic WKY 
rats. Treatment of diabetic SHR with T3 caused a slightly greater 
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decline in BW and an increase in LVW, leading to a restoration of 
LVW/BW. Treatment of nondiabetic SHR with T3 increased RVW 
significantly, and increased LVW/BW. Treatment of nondiabetic and 
diabetic WKY with T3 induced a relative left ventricular hypertrophy 
(LVW/BW), due apparently to a reduction in body weight. 
Ornithine Decarboxylase Activity. Left ventricular Ornithine 
Decarboxylase (ODC) activity in 23 week old nondiabetic SHR was not 
significantly different from that of either the WKY or the more 
outbred SD rat strain (Table 4, Study 3), confirming previous results 
(60). Diabetes reduced left ventricular (LV) ODC activity in both 
SHR and WKY to about the same extent (Table 4, Studies 1, 2, and 3). 
Insulin treatment prevented the decline in LV ODC activity in the WKY 
(Study 3), but not in the SHR group (Study 2). Treatment with T3 was 
partially effective in preventing the decline in LV ODC activity in 
both the SHR and WKY strains (Studies 2 and 3). The results of Table 
4, obtained at a substrate concentration of 25 uM, were confirmed at 
a saturating concentration of 200 or 400 uM ornithine (see Table 6, 
Appendix). Right ventricular ODC activity was not significantly 
affected either by diabetes or by any treatment (see Table 7, 
Appendix). The activity of the crude enzyme preparation seemed to 
display Michaelis-Menten kinetics in both the nondiabetic and 
diabetic state (Figure 1). The inset in Figure 1 depicts the 
Lineweaver-Burk plots for nondiabetic and diabetic SHR. It 
demonstrates that diabetes caused a decrease in V , but had no 
max 
effect on the apparent K for ornithine, in the SHR strain. A 
m 
similar pattern was evident in the WKY strain (Table 5). 
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TABLE I. Serum glucose, insulin, triiodothyronine and thyroxine levels of 
nondiabetic, diabetic and treated SHR, hKY and SD. 
Strain 
Group 
SHR 
Nondiabetic 
Diabetic 
Diabetic + T3 
Diabetic + I 
Nondiabetic + T3 
Nondiabetic 
Diabetic 
Di;; bet i.: + T 3 
Di.;l:octic + 
SD 
\'ond i 1; bl! tic; 
11 
12 
8 
6 
9 
6 
12 
11 
') 
Glucose 
(r.ig/dl) 
131 ± 164> 
633 + 55'" 
666 ± 77"' 
676 + 42* 
170 + 23 
636 + 60;': 
176 ± 1.8 
187 + 2) 
160 + l.~ 
Insulin 
(µU/r.il) 
83 ± 22 
20 ± 10* 
31 ± 14* 
193 ± 74'"* 
117 ± 78 
23 ± 6* 
.;1 ± 29* 
> ;oo .... 
161, ± 57 
l·~ l ± 37 
T 
(ngfdl) 
112 + 224> 
·~6 + 12* 
125 + 45 
61 + 18* 
101 ± 21 
86 ± 154> 
86 ± 12 
T, 
(pg/dl) 
0. I 7 ± 0. 11 '""' 
0. 21 ± 0.11"'"' 
3.05±0.40"' 
0.03 ± 0.01''"" 
1. ;o ± o. 61 
J.35±0.')7<!> 
V;l1u0s :1rr! r~e.1ns ±SD, 0bt:.iir.0d 8 \..'et-:ks aftc:r init:iat·i1)11 of di.1hc:t.c:s or 
tn".Jf:nt:Jlt frc;:l :;nin.il .s USQd jn StudiC'lS ~and J. r . ~, triied.0tllyr0ninc:; r.',' 
th:1r,);.:inc:; r' pro~:~r.licc zir:c: insulin. 
Signific:.;ntly diffl~1·1:nt frr)n the ne1~cii :i tC· L ) c gl·c;1!p (vithin st.1·.1in; p 
·:::':Sl};nlfic:~ntl:v diffpn;nt fn:-11 t:~~e 11c1~Jjab,"! Lic .: nd di a bc! tic grl~1:p.::; 
C.i i r hi 11 st r .1 in ; p < I) . ll 'i ) . 
< 0.05). 
1> Si~~nif 1 c:1r:t : l:; ... iif1t:r1)nt: f rf' l:l ::,,ndj.:\.:i:itic ~n-•1p.-..; (11 : l\~'l'EI1 :-:ti-.1i11s; i) <.. 0.US). 
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TABLE 2. Systolic arterial pressure and heart rates of nondiabetic, diabetic 
.;nd treated SHJ<, \.'KY .;nd SD. 
Strain 
Group 
Nondiabetic 
Diabetic 
Diabetic + t 3 
Diabetic + I 
::-londiabetic + t 3 
:\ondiabetic 
Di2betic 
Diabetic + r3 
DLil:etic + 
:-lcr.diabetic + T 3 
S 1l 
n 
12 
8 
6 
9 
6 
12 
11 
7 
SAP (r.ll:lHg) 
Week 0 ~eek 8 
175 + 16.P 198 ±: 13.P 
179 + 2!. 14·~ ±: 15* 
185 ± 16 18!. + 26 
175 ± 16 191 ± 13 
174 ±: 18 203 ±: 1-" 
127 + 11 1-'<3 ±: 11 
1211 ±: 11 I 2'l ±: 9 
127 + 9 
128 + 18 lid .:!: l f) 
12!1 + 9 
111 + l.'.'l .:!: 1-'1 
HJ< (beats/min) 
\,'eek 0 
399 + 32.P 
389 + 26 
374 ±: 27 
379 ±: 25 
402 ±: 20 
29!. ±: 19<1> 
310 ± 12 
307 .:!: 17 
301 ±: 12 
~21 + 20 
363 + 25¢ 
\.'eek 8 
468 + 37 
:oo ± 22r:> 
270 ± 18 
351 .:!: 26r:> 
\! :1ll~es :1n~ n1e:;1~s .:±:SD, l:bt.3)ned b1~fon? (\,\:i::..:. 0) .1n(i 8 • ..:i.?eks .ifll~r initiation ,)t 
di::J-:12.t:,~s nr trci,:t1~ent. fn)i.l ani;:i.sls u~1~d in SU:dies 2 .-i1:1l 3. 5/..P, sy~tolic 
.1rtcrial pi:esSt!re; HH, heart rat~; T.), triici.!~")1 hyro!1inr~; [, prot..:r.irh? zinc 
j 11 ~~I) ill . 
.. Slg11i fic:.-:ntl:-' diffGrl~nt f1cr.i the ;;(:ndi;:bt.:r-.ic :~ro11p (\Jif·hin ~tr.1i11; p < 1J.USJ. 
~·: ·::si~~nific.:ntly ,jjffQrent fr1~n thl? 1~endl.:hr:tic .:nd. di.Jbet:)c grc1!ps 
( ;.· i t. Ji i 11 St:·-' j 11; p ( I) . 0 ')) . 
•i> 1 )i!:nifi~:.1ntl:.r diffen.:nt fr1~r.i r;1 :· ndi;d;1:t_~i: grc_:.; 1ps (h2t~· c:1;11 s tr.,ins; p < O.U5). 
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TABLE 3. Body and heart \.:eights of nondiabetic, diabetic and treated SHR, \..'KY 
and SD. 
Strain ew LV RV LV/RV LV/B\./ 
Group 11 ( g) ( ng) (r.ig) (ng/mg) (ng/g) 
SHR 
Nondiabetic 12 3~2 ± 31¢> 980 + 92<!> 202 ± 27 !-4. 9.~ ± 0. 77<1> 2.87 ± 0.14¢ 
Diabetic s 191 ± 23"' 510 ± 69* 133 ± 26"' 3.95 + 0.91 2.68 ± 0. 17 
Diabetic + TJ 6 179 ± 24;': 571 ± 91 "' 11,3 ± 33"' !" 11 ± 0. 76 3. 18 ± 0. 18"'"' 
Diabetic + I 9 299 ± 23 i56 ± 65'""' 191 ± 27 1,. 0 l ± 0.56 2 .5 3 ± 0.13 
~ondiabetic + T1 6 331 ± 30 1013 +118 21'3 ± .'~ 4 ;'; ~·: !, • 11 ± 0.91 3 .08 ± 0. 25*"' 
\..'KY 
Nondiabetic 12 1,03 ± 25<!> 903 + 61¢ 229 ± .~ 1 1,. 01. ± 0. 70 2. 21. ± 0. 10<1> 
Diabetic II J.',O :!: 2.',;'; 7 'J6 .!:. 83 217 ± .',() 3. i 5 ± 0.59 2.36 + 0. 15 
Diabetic + Tl 30.'i + 1,Qo'; 890 ± 35 233 ± :n 3. 31, + 0 .8 1 2. 97 .!:. 0 . .'~ 7 ;·,~·: 
!)iabetic + !,JI ± 38 961 :!: 115 2.5·'• ± 73 J.97 + 0.87 2.n "" 0.08 
~c"n diab:t ic + T J ~81 + :'.6 JQ;6 ± 151 ;or; ± <;O J.60 .!:. 0 ;) ? ~I ~. •.·i + :J. 61•"'"' 
Si) 
:\ond iab"t ic ') 63l + 69'!> iO'? I ± 33<1> 309 ± 5S<l> J.62 + I). 53 1. 71 .!:. 0 . 11<:> 
\'al11p,; .!n~ 11eans ! <:D, {'bt.i i ;11')d 8 \..'CPkS .if t:1 : r initiation ()f di.~ hc:tE.:is or 
trP.;~tr1G11t. f l"Oi:l .-: 11 j r:;1 ls u:oed in St~dil~S ?. :1r:d l. Tl' l : riictiot·hyrc11int~; I' 
rrotami n1'? r. i n1: i r: "1;] in. 
Sig:1ifoc.-,ntlv .ii r f1"'n~nt f l"Ol!l t he~ i1(' 1H1 i, d,r:.t j <.: group ( 1.•i l hi n 
- t ra i 11; il < '). 05). 
,.,*Sig;1i fic.:;nt J:J .~ 1 l f.~rcnt r rori t hl? nondi :Jb<:t il: .1nd di a bt: tic g:·1'l!pS 
(".Ji th i fl st· r:1 i :1; ;) ( 0. 05) . 
·t> S jg n] r· i l: :~ n t· J :1 d j ff(;l"t?!~t f rl~l:i ;11::ind i.1h~1 j {~ gr~)\ipS (bet \..'tll":ll ~; t. J' .ii:: s; p < o .. J5). 
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TABLE 4. Left Ventricular ODC activity in non~iabetic, diabetic and treated 
SHR, \..1\Y and SD rats. 
Strain 
Group 
SHR 
~ondiabetic 
Diabetic 
Diabetic + I 
~ondiabetic + r 3 
t\'ondiabetic 
Diabetic 
Diabetic + T3 
Diabetic + 
~fond i:ibet ic + T 3 
SD 
\'cnJi.ibnr. ic 
STUDY 1 
123 
35 
99 
20 
I.EFT \"E\'HICULAR ODC ACTIVITY 
(pmol co2/hr/mg protein) 
n STUDY 2 n 
3 JOO + 16 8 
2 56 + 22"'' 5 
71 + 27'"" 6 
,,3 + 14'°' <] 
97 + 18 6 
2 87 + 23 8 
... I.') + 20"" 
STUDY 3 
66 + 13 
24 + 10"'' 
61 + 13 
~· •. ·.f + 1 J"' 
.'~ 2 ~ J.',~ .. ·, 
52 ~ 20 
; () :+: .'S 
li6 + l.'1 
V.11uP.s :i re '.7\P..-;nc; + SD f:'~•t.1!!~t~d H ,,,_.Q( ~ k~ :1ft:i:r i11it.i.J.ti1~:1 ot dj:;bt~t·t~s {)l' 
trP. ::. t ::H!lltS. f., 1:r)i1>d0 1h:.;rcnin1'll; f, ~)l"\)1.,1mine :~}r:t: jn~11l~;1. 
·· Si~nlfic:311ti:1 differPnt fr1)1a tht~ :'lt):1.lial:l~L)c gr,J11p (1..;it:hi11 ·nr.1in; 
p < I). 05). 
···· Sjgniflcantly ,jjff1?rEnt. fr..-'n t.}H~ 1~1);~di.1b~t · ic .in d di..!i.:1:·ti1.: g1·r'~ps 
(wilhi11 s :r.li11; p < 0.05). 
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n 
'· 
3 
·• 
' ·I 
') 
Figure 1. Ornithine decarboxylase (ODC) activity of nondiabetic and 
diabetic SHR left ventricle, at various substrate 
concentrations. Inset: Lineweaver-Burk Plot of left 
ventricular ODC activity. 
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TABLE 5. Left ventricul.:;r ODC kinetics in nondiabetic and 
diabetic SHR, \;).:y and SD rats. 
Strain Kn 1 , Vmax Gr cup Jl ( µM) (pmol "co2/hr/mg prot.) 
SHR 
Nondiabetic 1, 26.3 ± 9.9 111. 4 ± 21.5 
Diabetic J 23.7 ± 5.7 51. 2 ± 8. 8'
0
' 
1-'KY 
~ondiabetic ,, 26.0 ± 9.6 118. 5 ± 12. 7 
Diabetic .', 31. 6 ± 7. l 61. 0 ± 13. 2·:, 
Va.lues are neans ± SE!1, cbta.ined 8 weeks after initiation of diabetes or 
trcatr:ients. 
'' Signific~ntly different from the nondiabetic group ("1ithin strain; p <0.05). 
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DISCUSSION 
The first two related hypotheses of the proposed study, that ODC 
activity of nondiabetic, hypertrophic spontaneously hypertensive rat 
(SHR) left ventricle would be higher than that of the nonhypertensive 
rat strains, and that diabetes would exert a selective effect in the 
SHR, were not supported by the results. The rationale for the 
hypotheses was derived, in part, from the assumption that ODC 
activity could be associ~ted with both the development and 
maintenance of left ventricular hypertrophy in a variety of 
experimental models (3, 4, 10, 13, 17, 30, 40, 54, 60). SHR exhibit 
a relatively slow progressive increase in arterial pressure and left 
ventricular mass (52, 80, 84), characterized by a thickening of the 
left ventricular wall (left ventricular hypertrophy). Thus, this 
model of hypertrophy is similar to the cardiac alterations seen in 
essential (idiopathic) hypertension in humans (77, 80). 
Diabetes affects a number of variables which conceivably might 
influence the course of hypertrophy development in the left 
ventricle. One proposed etiologic factor in the development of 
hypertensive hypertrophy in the SHR model is an increase in either 
the activity of, or the myocardial responsiveness to, sympathoadrenal 
influences (1, 83). Catecholamines, the mediators of sympathetic 
activation, stimulate myocardial ODC activity and induce left 
ventricular hypertrophy (4, 9, 22, 30, 76). One consequence of 
untreated diabetes is interference with sympathetic activation of 
cardiac muscle, characterized in part bY. a reduction in the density 
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of beta adrenoceptors (16, 24, 79). Another proposed stimulus of 
cardiac ODC activity is physical stress on the ventricular wall (7). 
Left ventricular hypertrophy results in part from elevated wall 
stress secondary to abnormally increased total vascular resistance 
(80). Previous studies from this laboratory and others have shown 
that diabetes reduces arterial pressure of SHR (15, 58, 70), and thus 
would likely relieve the pressure load on the left ventricle. The 
depressor effect of diabetes in SHR was confirmed in the present 
study (Table 2). The earlier studies also showed that diabetes 
caused a relatively more pronounced reduction in whole heart and left 
ventricular m~ss in SHR than it did in the WKY strain, associated 
with an inconsistent reversal of left ventricular hypertrophy (15, 
58). 
The only available study of ODC activity in nondiabetic SHR 
myocardium was reported by Ruskoaho et al (60). They observed that 
left ventricular (LV) ODC activity was elevated in the SHR, relative 
to that of the WKY, only in young animals during the development of 
left ventricular hypertrophy. However, after left ventricular 
hypertrophy was established, beginning at about 20 weeks of age, the 
ODC activities of SHR and nonhypertensive WKY rat left ventricle were 
not different. The results of this study (Table 4), confirm those of 
Ruskoaho et al. (60). At 23 weeks of age, the activity of LV ODC in 
SHR was similar to that of the WKY and the more outbred SD rat. The 
results also show that the effect of diabetes on ODC activity was 
approximately equal in magnitude in the hypertrophic SHR and 
nonhypertrophic WKY left ventricle (Table 4). Thus, hypertrophy did 
not seem to predispose the left ventricle to the influences of 
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diabetes on LV ODC activity. These results are not consistent with a 
role of increased ODC activity in the maintenance of left ventricular 
hypertrophy in the SHR. 
Although diabetes did not exert a selective effect on 
hypertrophic myocardial ODC activity, it did exhibit a preferential 
action on the left ventricle versus the right in both the SHR and WKY 
rat strains (Table 4 and Table 7, Appendix). The data confirm and 
extend previous results from other laboratories, which showed that 
untreated diabetes depressed myocardial ODC activity after 8 days and 
4 weeks (14, 25, 69). However, these earlier studies did not 
distinguish between left and right ventricular ODC activity. The 
present results also seem to show that the apparent differences in 
ODC activity between left and right ventricles, present in 
nondiabetic animals, disappear after imposing chronic, untreated 
diabetes. The difference in workload between left and right 
ventricle "is much greater than the incremental increase in workload 
imposed on the left ventricle by hypertension (26). Even acute 
elevations in workload can stimulate ODC activity (7). In general, 
the data support the concept that myocardial ODC activity may be 
regulated by mechanical and hormonal influences. 
Stimulation of myocardial ODC activity by a variety of stimuli 
has been shown to precede the development of hypertrophic responses, 
and suggests that polyamine synthesis may be an important regulatory 
component of cardiac hypertrophy (9, 10, 17, 22, 30, 39, 40, 45, 60, 
62). It is now well established that virtually all stimulatory or 
trophic hormones cause an increase in ODC activity in their 
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appropriate target tissues (2). Although, the mechanism of one 
regulation has not been well defined, several have been proposed. 
First, as mentioned earlier, an increase in one activity in 
various tissues may be the result of an increase in the amount of 
enzyme protein which, in turn, results from either a decrease in 
degradation or an increase in synthesis of the enzyme, or both (61). 
This mechanism is supported by an observed accumulation of onc-mRNA 
in mouse kidney which had been induced by androgens (31, 64, 68). 
Such regulation by alteration in the rate of enzyme protein synthesis 
or degradation is unusual in mammalian cells. Regulation is usually 
accomplished by posttranslational modification (47), such as 
phosphorylation, thiol modification, and related mechanisms. In 
order for rapid changes to occur by the former mechanism, the protein 
must turn over rapidly. The bulk of the available data indicates 
that one has a half-life of approximately 10-20 minutes (40, 65, 67). 
Insulin has been shown to increase one activity in various cell 
cultures (5). This increase is due to the formation of new one mRNA 
and a subsequent rise in one protein (5). Mallette and Exton (38) 
observed an increase in liver one activity during ex vivo perfusion 
with a pharmacological dose of insulin. Finally, Conover (14) and 
Sochor (69) both found that insulin could prevent the decrease in 
cardiac one activity due to diabetes. However, it should be noted 
that the insulin-treated animals in these two studies were profoundly 
hypoglycemic. Insulin-induced hypoglycemia can markedly increase 
sympathoadrenal activity, which can increase cardiac one activity. 
Consequently, the prevention of the diabetic decrease in cardiac one 
activity may be a direct or indirect effect of insulin. 
26 
Second, some hormonal influences may affect the affinity of ODC 
for its substrate. Lau and Slotkin proposed that increases in 
cardiac ODC due to acute isoproterenol or T3 treatment resulted in 
the appearance of a form of the enzyme with an increased affinity for 
ornithine (33, 35). This suggests that the stimulation of cardiac 
ODC occurs through a Km shift in the absence of any increase in the 
number of ODC molecules. Millan (41) reported that both the K and 
m 
V of ODC were decreased in neonatal rat heart following hypertonic 
max 
saline injection. No changes were found in liver and other tissues, 
thus supporting the hypothesis that myocardial ODC may be under 
unique regulatory control. However, Flamigni et al. (19) observed a 
marked increase in V , with no change in the K , of myocardial ODC 
max m 
from rats treated with isoproterenol. Thus, the exact role of 
changing affinity states as a point of regulation remains unclear. 
Third, regulation of the enzyme may involve the expression of 
more than one isoform. Flamigni et al. (18, 19) also showed that two 
chromatographically distinct forms of ODC exist in the rat heart. 
Separable forms of ODC have been detected in other tissues (56), and 
do not seem to differ in their affinity for ornithine (42), but do 
differ with respect to their half-lives (49). Both forms are 
increased after isoproterenol treatment to the same extent, and thus 
the two forms cannot reasonably explain the isoproterenol induction 
of ODC (19). However, the analytical methods used do not eliminate 
the possibility of purification artifacts due to the high level of 
pyridoxal phosphate used during the extraction (48). When analysed 
by gel electrophoresis, no heterogeneity of ODC protein was observed 
with respect to size, but two forms were detected which varied 
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slightly in charge (65). The possible role of ODC isoforms in the 
hormonal regulation of the enzyme is not known. 
Finally, ODC antizymes may be targets of regulation. Canellakis 
has demonstrated the existence of a non-competitive protein inhibitor 
of ODC (antizyme) in various cell types, which is induced by 
polyamines (11). Recent evidence supports the existence of an 
antizyme molecule in the rat heart treated with putrescine and 
indicates that a significant amount of ODC occurs in an inactive, 
complexed form (20). The absolute and relative levels of ODC 
protein, as well as activity, may vary with different conditions or 
stimuli. The antizyme appears to have a half-life comparable to ODC 
and thus could constitute a sensitive modulator of enzyme activity 
(27). Also, the decline in ODC protein after exposure to exogenous 
polyami~es has been shown to occur more rapidly than the fall when 
protein synthesis is blocked by cycloheximide (11). This observation 
has led to the suggestion that another physiological role of antizyme 
may its involvement in the initial step of degradation of the ODC 
protein (48), perhaps by making ODC more susceptible to proteolytic 
cleavage (27). The development of specific antibodies and RIA 
techniques has permitted more thorough investigation of the mechanism 
of rapid ODC induction. No evidence has been found for the 
regulation of ODC enzyme protein by post-translational modifications 
or by changes in the content of activating or inhibitory factors. 
Seely and Pegg (65, 66) found an excellent correlation between the 
amount of ODC protein and the enzymic activity in induced rat liver 
and kidney. ODC activity declines very quickly in cells in response 
to exogenous polyamines (11) possibly through the induction of the 
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antizyme, and appears to be due to an increased degradation rate and 
a decreased rate of synthesis. However, there is no change in the 
content of ODC-mRNA, suggesting that the translation of ODC-mRNA may 
be affected by the polyamine content. In some instances the 
increased synthesis of ODC protein in response to acute treatment 
with ODC inhibitors is also not accompanied by any change in the mRNA 
content (50). Thus, it seems that overall regulation of ODC protein 
occurs both at the level of transcription of the ODC gene and at the 
level of translation of the ODC-mRNA. 
The presents results, which demonstrated that diabetes caused a 
decrease in the maximum velocity without affecting the apparent K of 
m 
ODC for ornithine (Figure 1 inset, and Table 5), are not inconsistent 
with mechanisms 1, 3, and 4 as discussed above. They do tend to rule 
out, however, those which invoke an alteration in the affinity of the 
enzyme for its substrate (mechanism 2 above). This is consistent 
with some preliminary results which show a decrease in the total 
activity of the enzyme in the cytosol and particulate fraction (Table 
8 Appendix). The present results also imply that diabetes causes a 
shift in the subcellular localization of the enzyme (Table 8, 
Appendix), as indicated by the ratio of ODC activity in the pellet 
versus the supernatant fractions. Obviously, these experiments need 
to be repeated in order to obtain a more definitive characterization. 
One explanation for this phenomenon may be an increase in the amount 
of antizyme-ODC complex. The ODC antizyme is a non-competitive 
protein inhibitor of ODC, which would decrease the velocity of the 
decarboxylase reaction, without affecting the K (27). The design of 
m 
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our experiments cannot define the role of antizyme in the diabetic 
decrease of LV ODC activity. 
Experimental diabetes also decreases absorption in the intestinal 
tract (8). Starvation of nondiabetic rats has been shown to depress 
ODC activity in normotensive hearts to the same extent as diabetes 
does (14). However, decreased sympathetic activity as well as a 
receptor concentration during fasting could contribute to the 
reduction of cardiac ODC activity (79). Also, serum T3 and insulin 
levels are both reduced during fasting and may contribute to the 
decrease in cardiac ODC activity (79). Consequently the overall 
influence of malabsorption secondary to diabetes remains unclear. 
Another possible explanation of the decrease of LV ODC due to 
diabetes may be due to changes in cellular ornithine concentration, 
which may have resulted in alterations in the rate of myocardial 
synthesis of ODC protein (8). Ornithine is formed from arginine by 
the enzyme arginase, and thus changes in ornithine concentration may 
be secondary to alterations in arginine content. Conceivably, a 
fraction of the ornithine substrate might originate from myocardial 
arginase in addition to the arginine obtained from the serum. 
Ornithine is primarily manufactured in the liver and is an essential 
part of the urea cycle. Ornithine concentration in human plasma 
ranges between 30 and 50 µM (71), which is close to the apparent K 
m 
of ODC in the left ventricle (Table 5). It is also known that human 
red blood cells contain arginase and can secrete ornithine in 
surprisingly high concentrations into the plasma (82). Finally, 
Brosnan et al. (8) showed that ornithine concentration actually 
increases in the liver during severe experimental diabetes. We 
30 
carried out preliminary experiments which demonstrated minimal 
arginase activity in the heart (Table 9, Appendix), confirming 
previous results (28). Thus, any role of myocardial arginase in the 
effects of diabetes on cardiac ODC activity seems highly unlikely. 
Insulin treatment prevented the decrease in LV ODC activity in 
diabetic WKY, but did not in the SHR strain (Table 4). Although 
insulin prevented the serum alterations of diabetes in the WKY, it 
did not reverse them in the diabetic SHR (Table 1). However, insulin 
restored SAP and HR in the SHR (Table 2) and partially or fully 
restored BW, LVW, and RVW (Table 3). The ineffectiveness of insulin 
in diabetic SHR may be due to inappropriate therapy, leading to poor 
metabolic control. These animals were sacrificed 15-20 hours after 
their last injection. Conover et al. (14) and Sochor et al. (69) 
both found that insulin could prevent the decrease in cardiac ODC 
activity due to diabetes. However, as mentioned previously, it 
should be noted that the insulin-treated animals in these two studies 
were profoundly hypoglycemic. Insulin-induced hypoglycemia can 
markedly increase sympathoadrenal activity, which can increase 
cardiac ODC activity. Consequently, the prevention of the diabetic 
decrease of cardiac ODC activity in these two studies may be a direct 
or indirect effect of insulin. Hu et al. (29) have described a 
temporal increase of liver ODC activity in response to 
pharmacological doses of insulin. Unfortunately, they·did not show 
any time points after 6 hours. Later time points would better reveal 
the effectiveness of insulin therapy on tissue OSC activity in 
diabetes. The enzyme's very short half-life may require constant 
stimulation in order to maintain normal levels in the myocardium. 
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This treatment group is presently being repeated with the aim of 
better control of the hyperglycemia in the diabetic SHR. 
Induction of ODC activity by different growth factors on various 
cultured cells seems to require a minimum concentration of specific 
ornithine decarboxylase-inducing amino acids, such as asparagine, in 
the medium (57). Growth factors, including insulin, appear to act 
synergistically with the inducing amino acid (57). Insulin has also 
been shown to increase amino acid transport in cultured embryonic 
chick heart cells (63). Thus, the inability of insulin to restore LV 
ODC activity in diabetic SHR may also have been related, in part, to 
decreased plasma or tissue concentrations of specific ODC-inducing 
amino acids during diabetes. 
T3 treatment of diabetic SHR and WKY restored serum T3 levels 
(Table 1) and partially prevented the decline in LV ODC activity 
(Table 4). It also prevented the depressions in HR and SAP of SHR 
(Table 2). Hypothyroidism, which is associated with diabetes (53), 
has been shown to decrease cardiac ODC activity (13), whereas 
injections of T3 stimulate it (12, 13, 34, 45, 46, 54). Raymondjean 
et al. (54) found that T3 induced a biphasic response of cardiac ODC 
activity, with peaks at 4 and 21 hours that were inhibited by 
cycloheximide, indicating that T3 increased the synthesis of new ODC 
molecules. The trough of this response could be explained by the 
complexing of ODC to antizyme, since there was an accumulation of ODC 
molecules that " ... were catalytically inactive but inununologically 
reactive ... " (54). 
In sununary, the results of this study show that chronic, 
untreated diabetes depresses ODC activity in the left ventricle, but 
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not the right ventricle, of the rat heart. This effect of diabetes 
is: 1) Not influenced by preexisting left ventricular hypertrophy in 
the SHR model of hypertension; 2) Reversible by insulin treatment 
which confers good metabolic control; 3) Partially reversible by T3 
treatment; and 4) Not associated with any apparent change in the 
affinity of the enzyme for its substrate. The results support the 
hypothesis that both insulin and thyroid hormone, along with 
mechanical stress on the ventricle, are important regulators of 
myocardial ODC activity. They also suggest that neither ODC activity 
nor its possible regulation by these factors is uniquely influenced 
by established left ventricular hypertrophy. 
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APPENDIX. RESULTS ANCILLARY TO MANUSCRIPT 
41 
Figure 2a,b. Myocardial Ornithine Decarboxylase activity is 
typically higher in weanlings than in mature adult. Thus, 
characterization of the enzyme was initially carried out in 21 to 35 
day old Sprague Dawley (SD) rat hearts. Figure 3a depicts the 
Michaelis-Menten kinetics of myocardif! ODC activity over 2 hours, 
obtained by isotopically diluting (1- C) L-ornithine with unlabelled 
L-ornithine to the desired concentration. The double reciprocal plot 
of weanling SD cardiac ODC f~tivity is shown in Figure 3b. The K is 
35 uM and v is 710 pmol co2 generated/hr/mg protein, obtaine~ by 
linear regr~~ion analysis. 
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Figure 3. Effect of increasing concentrations of enzyme supernatant 
at a fixed ornithine concentration of 25 uM and time of 2 hours on 
ODC activity in weanling SD rat hearts. 
44 
0 .10 
0.08 
~ 
_c 0.0 6 
.......... 
0 
E 
c 0.04 
0.02 
0 
0 
0.1 . 0.2 0.3 0.4 
VOLUME 
(mLs of sup<?rnatant) 
45 
Figure 4. Verification of linearity with time of myocardial ODC 
activity at a fixed enzyme supernatant volume (0.3 mL) and substrate 
concentration (SOuM). 
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Figure 5. Verificar!on of recovery of generated 14co from 
incubation media. C-NaHC03 was added to correct votume and 
concentration of incubation constituents (see Methods). Vials were 
acidified and allowed to incubate14or the indicated times. The 
results indicate that 967. of the co2 was recovered in one hour and 1007. recovery was obtained at four hours. 
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TABLE 6. Left ventricular ornithine decarboxylase (ODC) in nondiabetic, 
diabetic and treated SHR, ~KY and SD. 
Strain 
Group 
(Ornithine] 
SllR 
Nondiabetic 
Diabetic 
Diabetic + T3 
Diabetic + I 
Nondiabeti c + T3 
\'ondi»bctic 
Dia betic 
Di.1betic t r 3 
Di.1bP.t ic + 
SD 
STUDY l n 
400 µM 
204 3 
90 2 
187 2 
/,6 .~ 
Left Veniricular ODC Activity 
(pmol ~co2/hr/mg protein) 
STUDY 2 n STL'DY 3 
200 µM 200 µM 
178 + '•2 8 112 + 16 
89 + 73* 5 53 + 7* 
143 ! ·'~ 7 :';~ 6 
121 + 2 7 '" 9 
176 + 35 6 
168 ! '' . .:. , 3 113 t 
107 ! l )°'' 55 + ~~ .'i ~·~ 
76 
.! 1,0,,-,, 
90 + :, 5 
l 3!1 
.! (;0 
J J ! ! ;\ 
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4 
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!, 
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TABLE 7. Right Ventricular ODC activity in nondiabetic, diabetic and treated 
SHR, h~Y and SD rats. 
Strain 
Group 
SHR 
Nondiabetic 
Diabetic 
Diabetic + T3 
Diabetic + I 
Nondiabetic + 
\,'J<Y 
~ondiabetic 
Di;;betic 
Diabetic + T3 
Di .:; b!!t ic + 
\'ond iabl!t ic + 
~ D 
~ondial;!! t;c 
n 
9 
8 
6 
8 
T3 7 
8 
8 
6 
TJ 
:~ 
l' RV ODC Activity 
prnol ~co 2 generated/hr/mg protein 
~o + 25 
29 + 23 
46 + 26 
32 :!: l .', 
30 :!: 15 
15 :!: 18 
26 + 15 
:iO :!: 12 
.'~ 3 + JO 
'il ! 25 
56 
.!: ,-_, 
t. t: Patr::t:nts frc"'n ::11j1:-:;il s :....i~1'rl in Su:di~ :; 2 n.111i 3. 
p 1. «.1 t .i r:i i 1. e : ~ i n j· i ;1:-: 11 l j :1. 
CiA.: ll:1it".s : i: ;:-,\ ) 1 ''co ..., .~~"1 ~ 1 ' 1 - .-;.1-, ·: d / hr/r~.~ pr 0t l~i:1, 
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TABLE 8. Subcellular localization of ODC activity in nondiabetic and diabetic 
SHR and 1.l<Y. 
--------------------------------- ------ ---------------------------------------
Strain 
Group 
SHR 
Nondiabetic 
Diabetic 
1-"KY 
Nondiabetic 
Diabetic 
Values are 
previously 
ODC units; 
Pellet Supernatant Total Pellet 
n Supernatant 
2 12 l 66 187 l. 83 
2 82 21 103 3.91 
2 65 57 122 l. 14 
2 84 36 120 2. 33 
rneans of ODC activity from Supernatant of 5% homogenate as described 
in Met~~ds er frorn reconstitution of Pellet with 25 ~1 HEPES. 
pmol ~co2 generated / hr / mg protein, using 25 uM Ornithine. 
52 
TABLE 9. Arginase activity in liver and heart of adult male Sprague Dawley 
rats. 
Tissue n Arginase activity 
Liver 
Fresh 255 + 48 
Frozen ·~ 281 + 31 
Heart 
Fresh 5 0.25 + D.05 
.frozen 5 0.21 + 0.08 
Values are qeans ±SD fer Argin.ise ."ictivity deter1:1ined by the detection of ure.1 
generation. 
Arginase units: ·~oles of urea for1:1ed/1:1in/g tissue weight 
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